The FDA has withdrawn a proposed rule that would have required screening of certain cosmetics for asbestos, and the decision is drawing sharp backlash from critics who call the move a step backward for product safety.

The proposal at issue concerned standardized testing for asbestos contamination in cosmetic products — a risk most closely associated with talc-based formulations, where the mineral talc can occur in geological proximity to asbestos. Under the framework established by the Modernization of Cosmetics Regulation Act (MoCRA), Congress directed the FDA to develop a rule on asbestos testing in cosmetics that contain talc, making the issue one of the agency's mandated implementation tasks.

The withdrawal means formulators and quality teams will not, for now, face a uniform federal testing requirement for talc-containing products. That leaves the current patchwork in place: manufacturers continue to rely on existing methods and supplier certifications to verify talc purity, while state-level rules and litigation risk — rather than a binding federal standard — remain the primary compliance drivers.

The reaction has been blunt. Critics quoted in coverage of the decision called it "just crazy," arguing that a standardized, enforceable screening method is exactly what the sector needs after years of contamination concerns, recalls, and high-profile litigation tied to asbestos detected in cosmetic talc products. For safety advocates, the withdrawal removes a tool that would have created a level analytical playing field and a clearer legal baseline for enforcement.

For industry, the calculus is more mixed. A codified test method would have added documentation and laboratory workload to quality programs, but it also would have given manufacturers a definitive reference point — a single accepted procedure rather than a debate over which analytical technique counts. Without it, companies sourcing talc must continue to make their own choices about testing depth, method validation, and supplier audits, and those choices remain exposed to challenge in court and in the court of public opinion.

The stakes are not abstract. Asbestos is a known carcinogen with no accepted safe exposure level, and the detection of asbestos fibers in talc-based cosmetics has triggered product recalls and consumer lawsuits in recent years. Laboratories analyzing talc have long had to navigate methodological disputes, since amphibole and serpentine fibers can be difficult to distinguish and different techniques can yield different answers on the same sample. A federal standard was intended to settle those arguments.

The withdrawal also lands in the middle of MoCRA's broader implementation timeline, which has already required the industry to register facilities, list products, and adapt to new adverse event reporting and safety substantiation expectations. Each deferred rule shifts compliance planning: quality teams that anticipated building asbestos screening into release testing now face continued uncertainty about when, or whether, a federal requirement will materialize.

Procurement teams should read the decision as a signal that supplier qualification for talc remains a first-line control. Certificates of analysis, mine-level traceability, and third-party testing retain their full weight in the absence of a mandated federal screen.

The FDA has not, by this withdrawal, closed the door on asbestos regulation of cosmetics; the agency retains other tools, and MoCRA's statutory mandate on talc testing has not been repealed. What formulators, compliance leads, and buyers should watch next is whether the agency reintroduces a revised proposal — and on what method it settles.